IN8bio (INAB) Competitors $0.13 0.00 (-3.08%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$0.13 +0.00 (+0.79%) As of 05/21/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INAB vs. ASRT, PDSB, RPTX, IMMX, MGX, ADVM, GANX, SKYE, DTIL, and IKNAShould you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include Assertio (ASRT), PDS Biotechnology (PDSB), Repare Therapeutics (RPTX), Immix Biopharma (IMMX), Metagenomi (MGX), Adverum Biotechnologies (ADVM), Gain Therapeutics (GANX), Skye Bioscience (SKYE), Precision BioSciences (DTIL), and Ikena Oncology (IKNA). These companies are all part of the "pharmaceutical products" industry. IN8bio vs. Assertio PDS Biotechnology Repare Therapeutics Immix Biopharma Metagenomi Adverum Biotechnologies Gain Therapeutics Skye Bioscience Precision BioSciences Ikena Oncology IN8bio (NASDAQ:INAB) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends. Does the media prefer INAB or ASRT? In the previous week, Assertio had 4 more articles in the media than IN8bio. MarketBeat recorded 4 mentions for Assertio and 0 mentions for IN8bio. Assertio's average media sentiment score of 0.16 beat IN8bio's score of -0.50 indicating that Assertio is being referred to more favorably in the news media. Company Overall Sentiment IN8bio Negative Assertio Neutral Which has higher earnings and valuation, INAB or ASRT? IN8bio has higher earnings, but lower revenue than Assertio. Assertio is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIN8bioN/AN/A-$30.01M-$0.45-0.28Assertio$119.00M0.55-$331.94M-$0.32-2.14 Which has more volatility & risk, INAB or ASRT? IN8bio has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, Assertio has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Do insiders & institutionals believe in INAB or ASRT? 92.1% of IN8bio shares are owned by institutional investors. Comparatively, 49.0% of Assertio shares are owned by institutional investors. 9.5% of IN8bio shares are owned by company insiders. Comparatively, 4.0% of Assertio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer INAB or ASRT? Assertio received 88 more outperform votes than IN8bio when rated by MarketBeat users. However, 74.29% of users gave IN8bio an outperform vote while only 60.00% of users gave Assertio an outperform vote. CompanyUnderperformOutperformIN8bioOutperform Votes2674.29% Underperform Votes925.71% AssertioOutperform Votes11460.00% Underperform Votes7640.00% Is INAB or ASRT more profitable? IN8bio has a net margin of 0.00% compared to Assertio's net margin of -54.46%. Assertio's return on equity of 3.79% beat IN8bio's return on equity.Company Net Margins Return on Equity Return on Assets IN8bioN/A -197.15% -130.48% Assertio -54.46%3.79%1.81% Do analysts rate INAB or ASRT? IN8bio currently has a consensus price target of $6.00, suggesting a potential upside of 4,661.90%. Assertio has a consensus price target of $2.75, suggesting a potential upside of 300.99%. Given IN8bio's higher probable upside, equities analysts plainly believe IN8bio is more favorable than Assertio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Assertio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAssertio beats IN8bio on 9 of the 16 factors compared between the two stocks. Get IN8bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INAB vs. The Competition Export to ExcelMetricIN8bioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.44M$2.93B$5.37B$8.39BDividend YieldN/A1.72%5.22%4.10%P/E Ratio-0.1730.5026.8419.71Price / SalesN/A400.15392.34117.39Price / CashN/A168.6838.2534.62Price / Book0.223.286.794.50Net Income-$30.01M-$72.17M$3.23B$248.18M7 Day Performance-4.91%2.96%1.53%0.20%1 Month Performance-27.79%3.25%10.06%12.37%1 Year Performance-88.00%-28.29%16.72%7.04% IN8bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INABIN8bio3.1997 of 5 stars$0.13-3.1%$6.00+4,661.9%-87.5%$11.44MN/A-0.1720ASRTAssertio2.0041 of 5 stars$0.62+0.9%$2.75+346.9%-32.8%$58.94M$124.96M-0.8420Analyst ForecastGap UpPDSBPDS Biotechnology1.5773 of 5 stars$1.29+7.5%$9.00+597.7%-55.6%$58.92MN/A-1.1120Earnings ReportGap UpRPTXRepare Therapeutics3.0827 of 5 stars$1.36flat$4.50+230.9%-61.2%$58.33M$53.48M-0.68180Positive NewsIMMXImmix Biopharma1.9484 of 5 stars$2.09flat$7.00+234.9%-9.1%$58.17MN/A-2.469News CoveragePositive NewsMGXMetagenomi1.3493 of 5 stars$1.55+2.6%$14.75+851.6%-76.8%$57.94M$52.30M-0.59236Gap UpADVMAdverum Biotechnologies3.7742 of 5 stars$2.71-3.6%$26.60+881.5%-71.1%$56.62M$1M-0.45190Analyst RevisionHigh Trading VolumeGANXGain Therapeutics1.9727 of 5 stars$1.92-1.0%$8.20+327.1%-27.6%$56.50M$50,000.00-1.7520News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpSKYESkye Bioscience1.1286 of 5 stars$2.07+19.4%$16.60+703.9%-81.6%$56.07MN/A-2.3211Analyst ForecastDTILPrecision BioSciences3.4803 of 5 stars$5.22+1.8%$47.00+800.4%-64.4%$55.07M$68.70M87.01200Earnings ReportAnalyst ForecastIKNAIkena Oncology2.8358 of 5 stars$1.14+0.9%$3.00+163.2%-16.7%$55.01M$659,000.00-0.9370Positive News Related Companies and Tools Related Companies ASRT Competitors PDSB Competitors RPTX Competitors IMMX Competitors MGX Competitors ADVM Competitors GANX Competitors SKYE Competitors DTIL Competitors IKNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INAB) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IN8bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INAB Stock Free INAB Stock Alerts